Drug Profile


Alternative Names: HKI-272; PB-272

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer City of Hope National Medical Center; Memorial Sloan-Kettering Cancer Center; Pfizer; Puma Biotechnology; University of California at San Francisco
  • Class Antineoplastics; Nitriles; Pyridines; Quinolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Breast cancer
  • Phase II Non-small cell lung cancer; Solid tumours
  • Phase I/II Haematological malignancies

Most Recent Events

  • 12 Dec 2016 Phase-II clinical trials in Breast cancer (Metastatic disease, Combination therapy, Second-line therapy or greater, Locally recurrent) in United Kingdom (PO) (ISRCTN16945804)
  • 07 Dec 2016 Interim efficacy and adverse events data from a phase II SUMMIT trial presented at the San Antonio Breast Cancer Symposium (SABCS-2016)
  • 06 Dec 2016 Puma Biotechnology initiates enrolment in the Managed Access Program for HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumours in EU and other countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top